Phathom Pharmaceuticals, Inc. (PHAT)
5.74
-0.48
(-7.72%)
USD |
NASDAQ |
Oct 30, 16:00
5.85
+0.11
(+1.92%)
After-Hours: 20:00
Phathom Pharmaceuticals Shareholders Equity (Quarterly) : -347.64M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -347.64M |
| June 30, 2026 | -344.27M |
| March 31, 2026 | -336.96M |
| December 31, 2025 | -438.17M |
| September 30, 2025 | -422.53M |
| June 30, 2025 | -405.83M |
| March 31, 2025 | -338.38M |
| December 31, 2024 | -253.58M |
| September 30, 2024 | -187.11M |
| June 30, 2024 | -233.83M |
| March 31, 2024 | -148.50M |
| December 31, 2023 | -72.76M |
| September 30, 2023 | -17.77M |
| June 30, 2023 | 17.60M |
| March 31, 2023 | -90.20M |
| December 31, 2022 | -74.81M |
| Date | Value |
|---|---|
| September 30, 2022 | -26.42M |
| June 30, 2022 | -7.00M |
| March 31, 2022 | 38.04M |
| December 31, 2021 | 72.16M |
| September 30, 2021 | 103.48M |
| June 30, 2021 | 132.13M |
| March 31, 2021 | 164.34M |
| December 31, 2020 | 194.27M |
| September 30, 2020 | 156.39M |
| June 30, 2020 | 188.42M |
| March 31, 2020 | 208.70M |
| December 31, 2019 | 227.96M |
| September 30, 2019 | -152.46M |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -1.286M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 81.53B |
| Eli Lilly & Co. | 40.27B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 345.02M |
| Total Liabilities (Quarterly) | 692.66M |
| Debt to Equity Ratio | -1.598 |
| Current Ratio | 1.761 |
| Net Debt Paydown Yield | 0.64% |